Finance

Lists
Q3 2026 earnings • released • EPS miss -29.02% • Revenue beat +5.62%
See results
TNXP:NASDAQ
Tonix Pharmaceuticals Holding Corp
$3.24
0.00%
(0.00) 1D
$3.30
+1.85% (+0.060)
Pre-market
Closed: Nov 12, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNXP...
Mkt. cap
62.96M
Avg. vol.
1.12M
Volume
8.96K
52-wk high
$20.56
52-wk low
$3.21
EPS
-$12.92
Beta
1.90
Shares outstanding
19.43M
No. of employees
142
Mkt. cap
62.96M
Avg. vol.
1.12M
Volume
8.96K
52-wk high
$20.56
52-wk low
$3.21
EPS
-$12.92
Beta
1.90
Shares outstanding
19.43M
No. of employees
142
News stories
From web sources and news partners
Profile
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project. Wikipedia
About Tonix Pharmaceuticals Holding Corp
CEOSeth Lederman
Employees142
Founded2007
HeadquartersBerkeley Heights, New Jersey, United States
SectorHealth Care
IndustryBiotechnology
Websitetonixpharma.com
Analyst ratings
Based on 4 analysts giving stock ratings to TNXP in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for TNXP in the last 3 months.
Highest
Current $3.24
$40.00 (+1,134.57%)
Average
$23.50 (+625.31%)
Lowest
$14.00 (+332.10%)
Analyst
Recommendation
Action
Price target
Projected
Date
James Molloy
Alliance Global Partners
Buy
Maintained
$40.00
+1,134.6%
11/09/2026
Gary Nachman
Canaccord Genuity
Buy
Reiterated
$18.00
+455.6%
11/10/2026
Tiago Fauth
Raymond James
Buy
Reiterated
$14.00
+332.1%
11/09/2026
Stacy Ku
TD Cowen
Buy
Maintained
$22.00
+579%
10/21/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
$37.00
+1,042%
03/16/2026
Last report
Nov 9, 2026
Fiscal period
Q3 2026
-$2.89 / -$2.24
-29.02%miss
Revenue / Est. (USD)
17.23M / 16.32M
+5.62%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
5.39M
6.88M
13.54M
17.23M
Cost of goods sold
1.06M
1.58M
703.00K
1.25M
Cost of revenue
1.06M
1.58M
703.00K
1.25M
Research and development expenses
16.94M
18.21M
19.42M
25.82M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
35.68M
28.62M
35.96M
45.59M
Operating expense
52.62M
46.84M
55.38M
71.41M
Total operating expenses
53.68M
48.42M
56.08M
72.67M
Operating income
-48.29M
-41.54M
-42.54M
-55.43M
Other non operating income
32.00K
-3.00K
551.00K
741.00K
EBT including unusual items
-46.91M
-40.19M
-40.55M
-53.33M
EBT excluding unusual items
-46.91M
-40.19M
-40.55M
-53.33M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-46.91M
-40.19M
-40.55M
-53.33M
Net profit margin
-870.32%
-584.38%
-299.41%
-309.44%
Earnings per share
-3.98
-2.93
-2.47
-2.89
Interest and investment income
1.34M
1.35M
1.43M
1.36M
Interest expense
-
-
-
-
Net interest expenses
1.34M
1.35M
1.43M
1.36M
Depreciation and amortization charges
-
-
-
-
EBITDA
-47.80M
-40.98M
-41.92M
-54.79M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps